Understanding Indonesia's Regional Healthcare Markets

Published 05 November 2014

Keeping abreast of both the global and local medical market, with ever-changing economic climates and dynamic regulatory changes, can be a daunting task. Being able to understand the local operating market is essential now and in the future. Espicom’s country market reports provide in-depth interpretation of the medical device market, competitor analysis and growth forecasts for 5 years, all for over 70 countries worldwide. Alternatively, investigate the bigger picture with the Fact Books and Forecast reports.

Register for a FREE Executive Summary

Understanding Indonesia's Regional Healthcare Markets
Product Price

BMI View: Indonesia is one of the most promising markets for pharmaceutical and healthcare companies in South East Asia. The country's   large population, positive economic outlook and considerable disease burden bode well for growth in demand for drugs, medical devices and healthcare services.

We highlight Indonesia as one of the most promising markets for pharmaceutical and healthcare companies in South East Asia. Indonesia's public and private sector spending within the two sectors is set to increase significantly over the next decade, presenting a large and expanding commercial opportunity for drugmakers, medical device companies, hospital operators, health insurers and other service providers. Indonesia's demographic profile and economic outlook anchor our positive view of the overall commercial opportunities in the country. However, we do note there are several risks to bear in mind.

Key Growth Drivers Of Pharmaceutical & Healthcare Spending

Large, growing population and increasing life expectancies: Indonesia's total fertility rate (TFR) was 2.6 in 2012, indicating an expansion in the country's population. However, population growth is expected to slow, as TFRs stabilise in line with improving quality of life. Life expectancy in Indonesia is currently 70 years, but the rollout of universal healthcare and further uptake of pharmaceuticals will contribute to increasing life expectancy and therefore an ageing population. Over time, an ageing population will drive demand for pharmaceuticals and healthcare services.

Considerable burden of disease: mortality rates in Indonesia for a range of diseases and conditions are still high, relative to the country's development status. Indonesia also has the world's third largest tuberculosis burden behind India and China, with 91,000 annual deaths and 528,000 new infections every year. However, rising incomes, accelerating urban migration and dietary shifts indicate that diseases such as...

Register for a FREE Executive Summary

Espicom’s Understanding Indonesia's Regional Healthcare Markets Report allows you to explore Indonesia’s regional markets by giving you a practical evaluation of opportunity and risk at the under-appreciated sub-national level.

Rich in statistics, charts and maps, this is the one report you need to fully appreciate the Indonesia’s diverse regional health environments in the context of neighbouring provinces/states/territories and the national picture.

Written in association with Business Monitor International, this unique report uses data sourced in-house, providing analysis and forecasts from our experts covering key areas such as:

  • Healthcare Expenditure
  • Healthcare Facilities
  • Healthcare Personnel
  • Demographics
  • Economic Activity

Published by Espicom - experts in the pharmaceutical, medical devices and healthcare field for over 30 years, Espicom’s Understanding Indonesia's Regional Healthcare Markets Report brings together a range of often difficult to source information in one single, convenient and comprehensive publication.